A national study reveals that a significant number of U.S. adults with elevated low-density lipoprotein cholesterol (LDL-C) are not receiving the recommended lipid-lowering therapies, such as statins and PCSK9 inhibitors, resulting in missed opportunities to mitigate cardiovascular risks. Researchers analyzed NHANES data from nearly 5,000 adults, finding that 47% to 88% were eligible for treatment according to guidelines by the ACC, AHA, and ESC. Full adherence to these guidelines could decrease major cardiovascular events and save the U.S. healthcare system up to $32 billion annually.

Source: Springer Nature Link